Use of human amnion for microvascular interpositional grafts.
A major problem associated with vascular grafting employing an artificial graft is the inflammatory response provoked by the graft and subsequent complications of classical acute rejection phenomena when the graft is implanted subcutaneously into human volunteers. The favorable results obtained by a preliminary study of subcutaneous implantation of amnion in our laboratory have led us to a prospective study to determine its value as a vascular graft. Tubed conduits of glutaraldehyde-treated amnion were hand constructed of varying diameters and lengths. They were employed as segmental interpositional grafts in experimentally created femoral and aortic arterial defects in Sprague-Dawley rats. Patency rates varied from 60 to 90 percent, with all grafts showing remarkable reendothelialization within 3 to 4 weeks postoperatively. Morphology, antigenic reaction, blood flow, and patency of the different experimental amnion grafts were evaluated and compared to appropriate controls.
D000650:Amnion; D000818:Animals; D001011:Aorta / Q000473:pathology; D001705:Bioprosthesis; D001807:Blood Vessel Prosthesis; D005263:Femoral Artery / Q000473:pathology; D006083:Graft Occlusion, Vascular / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors; D014945:Wound Healing